Infertility Testing Market is expected to reach US$ 820.08 million by 2030

Female Infertility Testing Segmentto Hold Significant Infertility Testing Market Share During 2022–2030  

According to our latest study on "Infertility Testing Market Forecast to 2030 – Global Analysis – Type, Test Kits, Sample, and End User, Geography" the market is expected to reach US$ 820.08 million by 2030 from US$ 424.20 million in 2022.The market is expected to grow at a CAGR of 8.6% The report emphasizes the key factors driving the market and prominent players' developments. Factors such as the increasing cases of infertility in men and women and growing advancements in infertility testing propel the infertility testing market growth. However, lack of awareness and limitations associated with infertility testing kits impede the market growth.  

According to a study titled “Fertility and infertility: Definition and epidemiology,” published in Elsevier B.V., infertility is known to affect around 8–12% of couples across the world. The proportion is gradually increasing due to several causes such as modern lifestyles, illnesses, and the postponement of parenthood. In the male reproductive system, infertility is most often caused by problems ejecting semen, missing or small amounts of sperm, or abnormal shape (morphology) and movement (motility) of sperm. In females, infertility can be caused by abnormalities associated with the uterus, ovaries, fallopian tubes, and endocrine system. Factors such as increasing awareness about testing and changing lifestyles with increasing trends of unhealthy diets boost the market growth. However, the reluctance to introduce costly tests hampers the market growth. In addition, new advanced technologies are expected to bring new infertility testing market trends in the coming years.

To get sample Copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/brochure/TIPHE100001421

Consistent research and development studies are being carried out worldwide to gain a better understanding of the idiopathic world of infertility. Companies across the world are investing in the development of new test kits and medical aids that are likely to diagnose and treat infertility issues among men. In addition, the approval for hormonal therapy and its commercialization is likely to account for a significant milestone in treating infertility. In recent years, reproductive medicine has made remarkable progress owing to the application of artificial intelligence (AI) in sperm analysis and diagnosis. These innovations have improved understanding of male infertility and given new hope to couples struggling to conceive. In December 2023, India-based startup Arva Health launched an at-home fertility test. The test is designed to measure up to 12 hormone levels that influence fertility. The product is specially tailored for Indian women suffering from polycystic ovary syndrome (PCOS) and thyroid problems. In November 2023, an India-based fertility startup Inito obtained US$ 6 million in Series A funding for developing its hormone testing kit. The test measures estrogen levels and luteinizing hormone (LH) to predict fertile windows while measuring progesterone metabolite (PdG) to confirm ovulation. Follicle-stimulating hormone (FSH) is also measured to track follicle growth. The kit comes with a fertility monitor that connects to the mobile phone and allows women to access their diagnostic results via the Inito app, where they can track their fertile days and ovulation. In addition, metabolomics, genomics, and proteomics advances will help uncover new biomarkers for diagnosing sperm infertility. Therefore, such technological advancements are expected to boost the infertility testing market growth during the forecast period.

Infertility Testing Market, by Type:

Based on type, the infertility testing market analysis is carried out by considering the following segments: male infertility testing and female infertility testing. The female infertility testing segment held a larger market share in 2022. The male infertility testing segment is anticipated to register a higher CAGR of 9.2% during the forecast period. Declining female fertility rates, increasing prevalence of gynecological issues in women, busier lifestyles of working women leading to more stress, and low egg counts are among the main factors responsible for the high infertility testing market share. Additionally, the availability of many female infertility tests contributes to the market growth for the female infertility testing segment.

Infertility Testing Market, by Test Kits:

By test kits, the infertility testing market is segmented into human follicular stimulating hormone (FSH) test kits, human chorionic gonadotropin (HCG) hormone test kits, luteinizing hormone (LH) test kits, and others. In terms of revenue, the human follicular stimulating hormone (FSH) test kits segment dominated the infertility testing market share in 2022. The same is anticipated to register the highest CAGR of 9.2% during the forecast period.

Infertility Testing Market, by Sample:

The infertility testing market, based on sample, is segmented into blood, urine, and others. The blood segment held the largest market share in 2022 and is anticipated to register the highest CAGR of 9.1% during the forecast period.

Infertility Testing Market, by End User:

The infertility testing market, by end user, is categorized into hospitals & clinics, fertility centers, and homecare. The homecare segment held the largest market share in 2022 and is anticipated to register the highest CAGR of 9.0% during the forecast period.

Infertility Testing Market, by Geography:

The scope of the infertility testing market report encompasses North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America held the largest market share in 2022. The infertility testing market size in North America is likely to upsurge by 2030 owing to the high occurrence of infertility, increasing awareness of infertility testing among men and women, growing female population affected by PCOS, rising age of first pregnancy among women, and easy availability of infertility test kits through e-commerce websites. Also, changing lifestyles with increasing trends of unhealthy diets leading to infertility and gynecological disorders in men and women are responsible for the infertility testing market growth. Furthermore, technological advancements in ovulation monitors are bolstering the market growth in the region. Furthermore, the rising consumption of smoking and tobacco will lead to an increase in infertility cases, propelling the market growth. Growing demand for self-testing and remote monitoring testing among women and innovation of new products are expected to create profitable market opportunities. Nevertheless, Asia Pacific is expected to witness the fastest growth rate of 9.1% during the forecast period.

The infertility testing market report emphasizes prominent players' developments. Merck KgaA; Procter & Gamble; bioMerieux SA; Alere Inc.; Babystart Ltd.; bioZhena Corporation; Quidel Corporation; CENTOGENE N.V.; SCSA Diagnostics, Inc.; and Boditech Med Inc. are among the prominent players operating in the market.

Contact Us
Contact Person: Content Team 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com